|
End-of-day quote
Taipei Exchange
02/09/2026
|
5-day change | 1st Jan Change | ||
| 96.60 TWD | +11.29% |
|
+2.88% | +143.32% |
| 14/08 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 28/04 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 80.1B 2.52B 2.18B 2.05B 1.87B 3.49B 238B 3.52B 24.26B 9.42B 122B 9.47B 9.26B 400B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 63.83B 2.01B 1.73B 1.63B 1.49B 2.78B 190B 2.8B 19.33B 7.5B 97.05B 7.55B 7.38B 319B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
10% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +11.29% | ||
| 1 week | +2.88% | ||
| Current month | +1.05% | ||
| 1 month | +41.85% | ||
| 3 months | +149.94% | ||
| 6 months | +136.47% | ||
| Current year | +143.32% |
| 1 week | 82.2 |  | 109 |
| 1 month | 66 | | 109 |
| Current year | 33.1 | | 109 |
| 1 year | 15.1 | | 109 |
| 3 years | 7 | | 109 |
| 5 years | 7 | | 109 |
| 10 years | 2.7 | | 109 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 01/06/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 25/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 13/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 27/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 27/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.29% | +2.88% | +541.86% | +663.64% | 2.27B | |
| +0.09% | -2.38% | +57.93% | +108.02% | 1,034B | |
| +1.27% | +1.74% | +54.27% | +70.96% | 654B | |
| -0.08% | -1.45% | +22.26% | +77.34% | 459B | |
| +0.49% | -5.19% | +33.28% | +35.53% | 343B | |
| +0.27% | +3.26% | +29.76% | +47.50% | 307B | |
| +0.12% | -2.11% | +0.60% | +12.03% | 251B | |
| +0.20% | -0.47% | +52.74% | +72.53% | 237B | |
| +2.64% | -1.08% | -15.85% | -53.97% | 202B | |
| -0.18% | +0.85% | +32.51% | +98.71% | 186B | |
| Average | +1.63% | -1.80% | +80.94% | +113.23% | 367.39B | |
| Weighted average by Cap. | +0.49% | -3.31% | +38.88% | +67.91% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -23.43M -20.21M -19.04M -17.35M -32.43M -2.21B -32.67M -225M -87.49M -1.13B -87.99M -86.06M -3.72B | -1.36B -42.91M -37.01M -34.87M -31.77M -59.38M -4.05B -59.83M -413M -160M -2.07B -161M -158M -6.81B |
| Net Debt | -5.17B -163M -141M -132M -121M -225M -15.39B -227M -1.57B -608M -7.87B -612M -598M -25.84B | -16.27B -512M -442M -416M -379M -709M -48.39B -714M -4.93B -1.91B -24.74B -1.92B -1.88B -81.26B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | TWD 96.60 | +11.29% | 14,925,560 |
| 01/09/26 | TWD 86.80 | -9.21% | 18,514,084 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
